Clinical characteristics, molecular epidemiology and mechanisms of colistin heteroresistance in Enterobacter cloacae complex

Chunli Wei, Jiming Wu, Jisheng Zhang, Yanhua Liang, Kaixin Yu, Mingjing Liao, Xushan Liang, Jianmin Wang, Wenzhang Long, Jin Wang, Shijian Chen, Yang Yang, Xue Gong, Jie Li, Xiaoli ZhangFrontiers in Cellular and Infection Microbiology 2025 · DOI

Abstract

Colistin heteroresistance showed species-dependent variations in levels and prevalence rates. The colistin-heteroresistant mechanisms were complex, involving coordinated regulation of multiple genes. These results highlighted the need for tailored antimicrobial stewardship. In addition, the development of direct, reliable and rapid clinical methods for detecting heteroresistance is essential for improving infection management and prevention.

Introduction

Colistin serves as a critical "last-resort" antibiotic for treating infections caused by multidrug-resistant Gram-negative bacteria. However, the emergence of colistin heteroresistance presents a significant clinical challenge. Heteroresistance occurs when a bacterial population appears susceptible to an antibiotic in standard laboratory tests but contains a small, highly resistant subpopulation (often as rare as 1 in $10^6$ cells). This "stealth" resistance can lead to unexplained treatment failure, as the sensitive majority is eliminated while the resistant minority flourishes under selective pressure. This study investigates the prevalence, clinical risk factors, and molecular mechanisms of colistin heteroresistance within the Enterobacter cloacae complex (ECC), a group of opportunistic pathogens notorious for hospital-acquired infections.

Methods and Data

The researchers analyzed 212 non-repetitive clinical ECC strains isolated from a teaching hospital in Chongqing, China, between 2018 and 2023. The study employed Population Analysis Profiling (PAP), the "gold standard" for detecting heteroresistance, alongside Whole-Genome Sequencing (WGS) to identify species and genetic lineages. Transcriptomics (RT-qPCR) and efflux inhibition assays were used to elucidate the molecular drivers of resistance, while a retrospective case-control study identified clinical risk factors associated with these infections.

Mapping the Genomic Landscape

The study revealed that heteroresistance is not uniformly distributed across the ECC. Genomic analysis identified specific high-risk lineages, notably sequence types ST116 and ST56, where 75% of strains exhibited heteroresistance. These lineages appear to be genetically "primed" for resistance and are successfully disseminating in hospital environments.

Phylogenetic tree of 212 ECC isolates showing clades, species, MLST, and resistance profiles.

Within the complex, Enterobacter kobei showed the highest prevalence of heteroresistance (29.4%), while Enterobacter hormaechei, the most common species, was more frequently either fully sensitive or fully resistant. This species-specific variation suggests that treatment strategies may need to be tailored based on the specific member of the ECC involved.

Phenotypic Evidence of Heteroresistance

The use of PAP was essential for uncovering the hidden resistant subpopulations that routine hospital labs often miss. The study found that 24.4% of strains initially classified as sensitive were actually heteroresistant.

Population Analysis Profiling (PAP) curves demonstrating the presence of resistant subpopulations across different ECC species.

In some cases, these resistant subpopulations reached Minimum Inhibitory Concentrations (MICs) of $\ge$ 128 mg/L, significantly exceeding clinical breakpoints. While most resistant subpopulations remained stable over 50 generations of growth without antibiotics, some showed instability, reverting to sensitivity in the absence of antibiotic pressure. This highlights the dynamic and often transient nature of heteroresistance.

Molecular Mechanisms: The Two-Hit System

The molecular "wiring" of colistin heteroresistance in ECC involves a coordinated response. The resistance is primarily driven by the PhoPQ two-component system, which upregulates the arnA gene. This gene modifies the bacterial cell surface to repel the positively charged colistin molecules. Additionally, the AcrAB-TolC efflux pump plays a crucial role by physically removing the drug from the cell. Interestingly, the mgrB gene, often implicated in resistance in other species like Klebsiella, was found to play a minimal role in this context.

Clinical Implications and Risk Factors

A retrospective case-control study identified prior exposure to cephalosporin antibiotics within the previous three months as a significant independent risk factor for colistin-heteroresistant infections. This suggests that the use of other antibiotic classes can exert "collateral" selective pressure, favoring the emergence of heteroresistant strains. This finding emphasizes the importance of comprehensive antimicrobial stewardship that considers the broader impact of antibiotic use.

Conclusion

The high prevalence of colistin heteroresistance in ECC, particularly within specific lineages like ST116 and ST56, underscores the need for enhanced surveillance. The current diagnostic gap—where PAP is too slow for routine clinical use—must be addressed through the development of rapid molecular or phenotypic tests. Catching these "hidden" resistant populations in hours rather than days is essential for ensuring effective infection management and preventing treatment failure in vulnerable patients.

Summary updated

Abstract

Colistin heteroresistance showed species-dependent variations in levels and prevalence rates. The colistin-heteroresistant mechanisms were complex, involving coordinated regulation of multiple genes. These results highlighted the need for tailored antimicrobial stewardship. In addition, the development of direct, reliable and rapid clinical methods for detecting heteroresistance is essential for improving infection management and prevention.
BibTeX
@inproceedings{wei2025clinical,
  author = {Chunli Wei and Jiming Wu and Jisheng Zhang and Yanhua Liang and Kaixin Yu and Mingjing Liao and Xushan Liang and Jianmin Wang and Wenzhang Long and Jin Wang and Shijian Chen and Yang Yang and Xue Gong and Jie Li and Xiaoli Zhang},
  title = {{Clinical characteristics, molecular epidemiology and mechanisms of colistin heteroresistance in Enterobacter cloacae complex}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1536058},
}
Figure